MEGA™ Assay

Modernizing quality control in IVF

MEGA assures product consistency through:

- Analysis of pre-implantation embryo development and health by gene expression in addition to morphology
- Increased sensitivity for detecting embryotoxicity in raw materials prior to manufacture
- Assessment of efficacy at early stages of development

The mouse embryo assay (MEA) has long been used as the standard method for screening raw materials, media, and labware used in IVF clinics. However, the sensitivity of the MEA to detect cytotoxicity in materials has been questioned for many years. Organizations such as ASRM and ESHRE, as well as numerous publications, have called for a more relevant and sensitive test than MEA\(^1\),\(^2\),\(^3\). Furthermore, being based solely on morphology at a single point in time, the MEA is inherently limited in its capability.

Irvine Scientific has developed a genetic mouse embryo assay called MEGA™. Using embryos from a genetically-engineered mouse strain, MEGA employs fluorescence-based detection of developmentally-regulated gene expression to assess embryos throughout the development stages including at the earliest stages of growth. The result is a bioassay that is more sensitive to embryotoxic materials and provides more functional information at an earlier stage of development.

Figure 1. A healthy mouse embryo expressing Oct4-GFP at 48 hours (A). The same embryo displayed healthy morphology at 48 hours (B) to 96 hours (C). The blue fluorescence reflects DAPI staining of the nucleus of each cell.
Why MEGA was developed

With the use of in vitro fertilization (IVF) and other assisted reproductive technologies (ART) expanding worldwide, safety is an increasingly important concern. Regulatory bodies, clinics, and patients have raised their expectations on quality control and raw material sourcing. MEGA was developed to address these expectations.

As a manufacturer of IVF media, one of our primary goals is to apply the most rigorous quality control processes available to evaluate raw materials. This process is particularly important for complex components such as oil and human serum albumin. With MEGA, our ability to detect suboptimal components is significantly improved. Further enhancements to MEGA, afforded by new strains of genetically modified embryos, may enable additional improvements to the reagents and materials used in ART/IVF.

Reduce concerns about toxicity with the power of genetic engineering

MEGA employs a functional molecular biomarker to improve the detection of toxic media or any other environmental stress that may negatively impact early development. The assay measures the level and location of fluorescence produced by green fluorescent protein (GFP), which is expressed under the control of the Oct4 promoter (also known as Pou5f1). Regulation of Oct4 expression is one of the most critical early indicators of normal embryonic development. Combined with traditional morphological evaluations, MEGA monitors both the early and late stages of development.

Unlike the traditional MEA, MEGA can harness the power of genetic engineering to further enhance and refine our capability of improving assisted reproductive technologies (ART)/IVF media and products.

Figure 2. Normal expression of Oct4-GFP (A) during early embryogenesis at 48 hours reflects healthy development in optimal culture conditions, corroborated by morphology (B). Compare this to low expression of Oct4-GFP seen in suboptimal conditions (C) even though morphology appears normal (D). MEGA facilitates early detection of embryotoxicity and abnormal embryo development. The blue fluorescence reflects DAPI staining of the nucleus of each cell.
Improving quality control through raw material qualification with MEGA

Irvine Scientific operates a robust raw material and supply chain qualification process. Stringent testing of raw materials using the MEGA assay prior to their use in finished products provides extra assurance of quality.

**MEGA Embryo Preparation**

- Embryos expressing Oct4-GFP (one-cell stage) are harvested from transgenic mice
- Fresh embryos with normal morphology and 2 pronuclei are pooled and randomly allocated for test and control conditions

**Raw Material Preparation**

- High risk raw materials received from qualified vendors prepared for testing (HSA, alpha beta globulin and oil)
  - Test HSA is prepared with control media
  - Test alpha beta-globulin is prepared with control media
  - Test and control oil will be laid over control media

**MEGA Assay run**

- Petri dishes with 20 µL droplets of culture media are prepared with a mineral oil overlay. Embryos are placed into test and control media (overlaid with test or control oil) for 96 hour incubation.

**Results analyzed over 96 hours**

- At 48 hours: Early fluorescent intensity (EFI) is assessed and embryos are ranked as having sub-normal (A, B) or normal (C, D) expression levels. Culture conditions resulting in lower proportions of normal-EFI embryos are considered abnormal or suboptimal.
- At 96 hours: Embryos checked for normal development into blastocysts
  - Oct4-GFP expression is localized to the inner cell mass

**Approved raw materials used to manufacture final products**

**Finished products undergo additional quality control testing**
MEGA shows increased sensitivity to detect suboptimal quality and toxicity

EFI eliminated suboptimal quality protein in the screening of 5 different HSA lots

To demonstrate the added sensitivity of MEGA, human serum albumin (HSA) was tested across five different lots (n=43 embryos per lot). While all lots showed no differences for 8-cell morphology at 48h with standard MEA, MEGA detected suboptimal performance of 2 lots (A and D) from their lower early fluorescence intensity (EFI). Subsequently, lot A was rejected based on morphology (<80% blastocysts) and lower EFI, while lot D was rejected based on lower EFI (morphology marginally passed)⁴.

<table>
<thead>
<tr>
<th>Lot #</th>
<th>≥ 8-cell morphology (%)</th>
<th>High EFI (%)</th>
<th>96 hr E/H Blastocysts (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSA-A</td>
<td>95.5</td>
<td>86.4</td>
<td>72.7</td>
</tr>
<tr>
<td>HSA-B</td>
<td>95.3</td>
<td>90.7</td>
<td>86</td>
</tr>
<tr>
<td>HSA-C</td>
<td>97.7</td>
<td>93</td>
<td>93</td>
</tr>
<tr>
<td>HSA-D</td>
<td>97.7</td>
<td>81.4</td>
<td>83.7</td>
</tr>
<tr>
<td>HSA-E</td>
<td>95.3</td>
<td>95.3</td>
<td>95.3</td>
</tr>
</tbody>
</table>

Table 1. Early Fluorescence Intensity at 48h was predictive of early/hatching blastocyst rates at 96h when MEGA was used to screen lots of HSA. Red highlights indicate lower proportion of normal EFI and corresponding lower or marginal E/H rates of suboptimal lots of protein that would be rejected by MEGA quality control testing.

MEGA is more sensitive at detecting toxicity in oil than standard MEA

An oil dose-response experiment was used to assess the sensitivity of MEGA to detect embryotoxicity and sub-optimal culture conditions. Pou5f1-GFP embryos cultured under oil overlays containing 0 (control), 5 or 10% previously identified adulterated (PID) oil were evaluated for embryo expression (EFI) at 48 hours and development at 96 hours (E/H blastocysts).

![Figure 3](image-url) Morphology alone was less sensitive than EFI in detecting PID oil. Morphology was a good indicator in the 10% condition but did not detect toxicity in the lower 5% condition. EFI at 48hr did detect the toxic component in the 5% PID condition showing increased sensitivity compared to morphology. MEGA has repeatedly demonstrated similar efficacy during assay development⁴.

Quality through scientific innovation is a core tenet at Irvine Scientific. MEGA was developed to meet customer expectations for media of consistently high quality, and to create a new standard of embryotoxicity detection that would allow further improvements in ART/IVF.

Strict testing of raw materials is just one facet of the quality control systems at Irvine Scientific. We were one of the first ART manufacturing companies in the USA to receive ISO 13485:2003 certification of our Quality System. Products are manufactured in accordance with the Current Guidelines for Manufacture of In Vitro Diagnostic Products and the Good Manufacturing Practices (cGMP) for Medical Devices.

Formulations use WFI Grade Water and chemicals that meet USP and ACS standards where available. All products are membrane-filtered and aseptically processed according to manufacturing procedures which have been validated to meet a sterility assurance level of 10⁻³. Every batch of medium is thoroughly tested for functionality, endotoxin level pH, osmolality and sterility. Results are provided in lot-specific Certificates of Analysis.

With the exception of a small subset of ancillary products, all key products for IVF are CE marked and FDA cleared. Quality and regulatory management systems ensure compliance with the broadest scope of regulatory requirements, including ISO 13485:2012, FDA’s QSR, and the European Medical Devices Direction (93/42/EEC).

Raw materials tested by MEGA are used in:

- Human Serum Supplement
- Dextran Serum Supplement
- Serum Substitute Supplement
- Oil for Embryo Culture
- Media supplemented with protein
## Protein supplements

<table>
<thead>
<tr>
<th>ITEM</th>
<th>CATALOG #</th>
<th>SIZE</th>
<th>ADDITIONAL INFORMATION</th>
<th>SHELF LIFE</th>
<th>STORAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Serum Albumin (HSA)</td>
<td>9988</td>
<td>12 × 5 mL</td>
<td>Saline solution containing total protein 10% w/v, 100% HSA.</td>
<td>3 years*</td>
<td>2–8°C</td>
</tr>
<tr>
<td>Serum Substitute Supplement™ (SSS™)</td>
<td>99193</td>
<td>12 × 12 mL</td>
<td>Saline solution containing 6% total protein w/v: 84% HSA and 16% alpha and beta globulins in saline.</td>
<td>2 years*</td>
<td>2–8°C</td>
</tr>
<tr>
<td>Dextran Serum Substitute (DSS)</td>
<td>9301</td>
<td>12 × 12 mL</td>
<td>Saline solution containing total protein 5% w/v: 100% HSA (50 mg/mL, 5% w/v), dextran (20mg/mL, 2% w/v) as non-protein alternative to globulins.</td>
<td>2 years*</td>
<td>2–8°C</td>
</tr>
</tbody>
</table>

## Oil for embryo culture

<table>
<thead>
<tr>
<th>ITEM</th>
<th>CATALOG #</th>
<th>SIZE</th>
<th>ADDITIONAL INFORMATION</th>
<th>SHELF LIFE</th>
<th>STORAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oil for Embryo Culture</td>
<td>9305</td>
<td>100 mL, 500 mL</td>
<td>Ready-to-use, sterile, light mineral oil.</td>
<td>2 years*</td>
<td>15–30°C</td>
</tr>
</tbody>
</table>

## Media containing proteins qualified by MEGA

<table>
<thead>
<tr>
<th>ITEM</th>
<th>CATALOG #</th>
<th>SIZE</th>
<th>ADDITIONAL INFORMATION</th>
<th>SHELF LIFE</th>
<th>STORAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous Single Culture® Complete (CSCM-C)</td>
<td>90165</td>
<td>2 × 20 mL</td>
<td>Ready-to-use, pre-supplemented with Human Serum Albumin (5% v/v HSA), for a final total protein concentration of 5 mg/mL.</td>
<td>2 years*</td>
<td>2–8°C</td>
</tr>
<tr>
<td>Multipurpose Handling Medium® - Complete (MHH®-C)</td>
<td>90166</td>
<td>100 mL, 500 mL</td>
<td>Ready-to-use. Contains key amino acids, 0.5 % HSA, gentamicin 10 mg/L.</td>
<td>1 year*</td>
<td>2–8°C</td>
</tr>
<tr>
<td>Vit Kit®-Freeze</td>
<td>90133-SO</td>
<td>ES, 2 × 1 mL, VS, 2 × 1 mL</td>
<td>For use with oocytes (MII), pronuclear (PN) zygotes through day 3 cleavage stage embryos and blastocyst stage embryos.</td>
<td>1 year*</td>
<td>2–8°C</td>
</tr>
<tr>
<td>Vit Kit®-Thaw</td>
<td>90137-SO</td>
<td>TS, 4 × 2 mL, DS, 1 × 2 mL, WS, 1 × 2 mL</td>
<td>For use with oocytes (MII), pronuclear (PN) zygotes through day 3 cleavage stage embryos and blastocyst stage embryos.</td>
<td>1 year*</td>
<td>2–8°C</td>
</tr>
<tr>
<td>Sperm Washing Medium</td>
<td>9983</td>
<td>12 × 12 mL, 100 mL</td>
<td>Ready-to-use outside the incubator. Contains 5 mg/mL HSA. Add preferred antibiotics.</td>
<td>2 years*</td>
<td>2–8°C</td>
</tr>
<tr>
<td>Sperm Maintenance Medium</td>
<td>99176</td>
<td>100 mL</td>
<td>Ready-to-use, egg yolk- and antibiotic-free. Contains 28 % (v/v) glycerol, 2 % (w/v) HSA.</td>
<td>2 years*</td>
<td>-10°C</td>
</tr>
<tr>
<td>7 % Polyvinylpyrrolidone (PVP) Solution with HSA</td>
<td>90121</td>
<td>5 × 0.5 mL</td>
<td>Decrease sperm motility for easier micromanipulation during ICSI. Contains 5mg/mL HSA.</td>
<td>6 months*</td>
<td>2–8°C</td>
</tr>
<tr>
<td>10 % Polyvinylpyrrolidone (PVP) Solution with HSA</td>
<td>90123</td>
<td>5 × 0.5 mL</td>
<td>Decrease sperm motility for easier micromanipulation during ICSI. Contains 5mg/mL HSA.</td>
<td>6 months*</td>
<td>2–8°C</td>
</tr>
</tbody>
</table>

*From date of manufacture

**Find local contacts and ordering information at www.irvinesci.com**

Irvine Scientific®, the Irvine Scientific logo, MEGA™, Continuous Single Culture®, Vit Kit®, Multipurpose Handling Medium® (MHH®), Serum Substitute Supplement™ (SSS™) are trademarks of Irvine Scientific Sales Company, Inc.

© 2017 Irvine Scientific P/N 10696ART Rev.0